Fig. 3.
Antitumor effect of CRT0066101 on the growth of human bladder cancer in nude mice. Athymic NCr-nu/nu mice (6-week-old) were implanted subcutaneously with 3 × 105 UMUC1 cells. The treatment started after the tumors were established in the mice, and mice were randomized into two groups (n = 10 mice/group) and administered with 100 μl of 5% dextrose (Vehicle) or with CRT0066101 (120 mg/kg/day) dissolved in 100 μl of 5% dextrose (CRT0066101), respectively. Treatment was administered 3 days per week by oral gavage for 25 days. Tumor volumes were recorded three times a week, as described in “Materials and methods”. Mice were euthanized 2 h after the last dose of the therapeutic regimen. P < 0.0001 for the CRT0066101-treated group vs. the vehicle-treated group at day 25 of the treatment